EP 4171233 A1 20230503 - CRYSTAL FORMS OF 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL]PIPERAZIN -1-YL]ETHYL PYRIDINE-3-CARBOXYLATE AND METHODS OF SYNTHESIS
Title (en)
CRYSTAL FORMS OF 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL]PIPERAZIN -1-YL]ETHYL PYRIDINE-3-CARBOXYLATE AND METHODS OF SYNTHESIS
Title (de)
KRISTALLINE FORMEN VON 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL)PIPERAZIN -1-YL)ETHYL PYRIDIN-3-CARBOXYLAT UND SYNTHESEVERFAHREN
Title (fr)
FORMES CRISTALLINES DE 2-[4- [(2,3,4-TRIMÉTHOXYPHÉNYL)MÉTHYL]PIPÉRAZIN-1-YL]ÉTHYL PYRIDINE-3-CARBOXYLATE ET PROCÉDÉS DE SYNTHÈSE
Publication
Application
Priority
- US 202063046120 P 20200630
- US 202063046123 P 20200630
- US 2021039305 W 20210628
Abstract (en)
[origin: WO2022005928A1] The invention provides polymorphs of a compound of Formula (X). The invention also provided pharmaceutical compositions containing polymorphs of the compound and methods treating conditions in a subject by providing polymorphs of the compound.
IPC 8 full level
A01N 43/04 (2006.01); A61K 31/675 (2006.01); A61K 39/395 (2006.01)
CPC (source: EP IL KR)
A61K 31/496 (2013.01 - EP IL KR); A61P 9/00 (2018.01 - KR); C07D 213/80 (2013.01 - EP KR); C07B 2200/13 (2013.01 - KR)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2022005928 A1 20220106; AU 2021299266 A1 20230202; CA 3188286 A1 20220106; CN 116056711 A 20230502; EP 4171233 A1 20230503; IL 299547 A 20230201; JP 2023532330 A 20230727; KR 20230031320 A 20230307
DOCDB simple family (application)
US 2021039305 W 20210628; AU 2021299266 A 20210628; CA 3188286 A 20210628; CN 202180056396 A 20210628; EP 21833175 A 20210628; IL 29954722 A 20221227; JP 2022581465 A 20210628; KR 20237003155 A 20210628